MAYOLY SPINDLER Committed to your health. Every day - 19-INS-319
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
MAYOLY SPINDLER
Committed to your
health.
Every day.
19-INS-319
OUR AMBITION
Become an
international
reference
in gastroenterology
and dermo-cosmetics
2
CONTENTS
OUR ASSETS OUR FIELDS OF OUR EMPLOYEES’
A French company EXPERTISE COMMITMENT
An independent company Pharmaceuticals Our values
An extensive global footprint Diagnostic A responsible company
Dermo-cosmetics
Contract Development &
Manufacturing
3
CORPORATE PRESENTATION 08/07/2019
OUR ASSETS
a French company
▪ Three manufacturing facilities near Paris, 1 in Chatou
(West of Paris) and 2 in Dammarie-les-Lys (East of Paris).
▪ Over 900 employees worldwide, including nearly 600 in
France.
▪ Turnover: €182 million in 2018.
▪ 70% of products sold are made in France.
▪ An economic player contributing to France’s status as
one of the world’s leading pharmaceuticals exporters*.
▪ Exported production : €51 million
* Source: LEEM (French Pharmaceutical Companies Association)– Economic report, 2016
issue.
4
CORPORATE PRESENTATION 08/07/2019
OUR ASSETS NET CONSOLIDATED TURNOVER
an independent company 2009-2018 (€ million)
200 190
182
180 167 173
159 161
160
154
145
▪ Founded in 1909: for more than a century, an 140 126
138
entrepreneurial adventure. 120
100
▪ Still an entirely family-owned company. 80
60
▪ Financial independence, a main performance driver. 40
20
0
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
5
CORPORATE PRESENTATION 08/07/2019
OUR ASSETS
an extensive global footprint
▪ Established worldwide in more than 70 countries
generating 41% of overall turnover
▪ Dynamic subsidiaries: in Europe, Eastern Europe, Asia and
Latin America (26% of international turnover in 2018)
▪ Business partners committed for the long term
▪ A proactive development policy
▪ With the acquisition in 2016 of Kibion, a Swedish company
principally operating in Germany and the Middle East,
Subsidiaries
Mayoly Spindler has become one of the world leaders in the
detection and control of Helicobacter pylori infections. Distributors
6
CORPORATE PRESENTATION 08/07/2019
OUR FIELDS OF
EXPERTISE
7
PHARMACEUTICALS
8
PHARMACEUTICALS BREAKDOWN OF TURNOVER
Our historical pillar of development BY BUSINESS SECTOR IN 2018
▪ Pharmaceutical sector: 72% of overall turnover in Diagnostic
13 million €
CDMO*
12 million €
2018
▪ Gastroenterology: 80% of our pharmaceutical Dermo-cosmetics
26 million €
7%
7%
business.
13 %
▪ A portfolio of therapeutic solutions spanning
speciality care, primary care and self-medication.
72 %
▪ An investment in collaborative R&D in
gastroenterology.
Pharmaceuticals
131 million €
* Contract Development & Manufacturing Organization
9
CORPORATE PRESENTATION 08/07/2019
OUR THERAPEUTIC SOLUTIONS PORTFOLIO IN
GASTROENTEROLOGY
Rx OTC
Biliary lithiasis Acid reflux
Biliary cirrhosis
Travel sickness
Helicobacter pylori
Gaz
Abdominal pains
Digestive and renal
Crohn’s disease elimination functions
Pancreatic insufficiency Heartburn
Cystic fibrosis
Probiotics/Gut flora
Colonoscopy
Constipation
10
CORPORATE PRESENTATION 08/07/2019L’ACTIVITE
DIAGNOSTIC
DIAGNOSTIC
PRÉSENTATION À DESTINATION 11
08/07/2019
EXCLUSIVE DES INSTITUTIONNELSDIAGNOSTIC BREAKDOWN OF TURNOVER
Our strategic pillar of development BY BUSINESS SECTOR IN 2018
Diagnostic
13 million € CDMO*
12 million €
▪ In 2016, Mayoly Spindler acquired Kibion, the world 7%
Dermo-cosmetics 7%
leader in fast and reliable urea breath testing machines 26 million €
and tests for the diagnosis and eradication control of
13 %
Helicobacter pylori.
▪ In 2019, Mayoly Spindler creates Mayoly Diagnostic, the 72 %
business unit dedicated to the devlopment of the
Helicobacter pylori infection diagnosis business.
Pharmaceuticals
131 million €
* Contract Development & Manufacturing Organization
12
CORPORATE PRESENTATION 08/07/2019 08/07/2019DIAGNOSTIC
Our strategic pillar of development
▪ 95% of duodenal ulcers and 70% of gastric ulcers are
attributable to Helicobacter pylori’s infection.
▪ Nearly 4 billion people worldwide are infected.
13
CORPORATE PRESENTATION 08/07/2019 08/07/2019DERMO-COSMETICS
14DERMOCOSMETICS BREAKDOWN OF TURNOVER
Topicrem, the science of hydration BY BUSINESS SECTOR IN 2018
▪ Topicrem: n°1 in body moisturizing milks in Diagnostic
13 million € CDMO*
pharmacies in France since 2013*. Dermo-cosmetics
12 million €
26 million €
▪ High-quality manufacturing standards recognized 7%
7%
on an international level.
13 %
▪ All worldwide production of Topicrem is made in
France (Dammarie-Les-Lys).
▪ An international brand (50% of Topicrem sales 72 %
generated outside of France).
Pharmaceuticals
131 million €
* Source : IQVIA — Pharmatrend PharmaOne (2016-2018) Pharmatrend
NMNM (2013-2016)— marché des hydratants émollients corps femme en
lait/lotion — 2013 a 2018 — en volume.
* Contract Development & Manufacturing Organization
15
CORPORATE PRESENTATION 08/07/2019PRODUCTION &
CONTRACT
MANUFACTURING
16PRODUCTION & CONTRACT
MANUFACTURING BREAKDOWN OF TURNOVER
BY BUSINESS SECTOR IN 2018
Technical prowess and responsiveness
Diagnostic CDMO*
▪ Three manufacturing facilities near Paris, 1 in
13 million € 12 million €
Chatou (West of Paris) and 2 in Dammarie-les-Lys (East Dermo-cosmetics
7%
of Paris). 26 million €
7%
▪ A softgel capsules expertise requiring a particular 13 %
technicality.
▪ A light and reactive structure that adapts to the 72 %
requirements of our customers.
Pharmaceuticals
131 million €
* Contract Development & Manufacturing Organization
17
CORPORATE PRESENTATION 08/07/2019PRODUCTION & CONTRACT
MANUFACTURING
Technical prowess and responsiveness
▪ A diversified offer: pharmaceuticals,
nutraceuticals, dermocosmetics
▪ Various galenic forms: soft capsules, tablets,
capsules, suppositories, oils, emulsions, gel, micellar
solutions…
18
CORPORATE PRESENTATION 08/07/2019OUR EMPLOYEES’
COMMITMENT,
CENTRAL TO OUR
SUCCESS
19OUR VALUES
RESPONSIBILITY RESPECT PRAGMATISM
Our performance is the result of the talent of our employees who, every day, share ambitious
projects
and a test for challenge.
Our corporate culture is reflected in the empowerment of our teams, the opportunity to take
initiatives and the pragmatism of each individual.
Mayoly Spindler is a company where respect goes hand-in-hand with growth,
fostering the well-being of everyone.
20
CORPORATE PRESENTATION 08/07/2019A RESPONSIBLE COMPANY
▪ OUR MAYOLY, our corporate responsibility programme.
▪ Three priorities: workplace well-being, commitment to
the community and care for the environment.
▪ Projects designed and coordinated by employees,
working in the general interest.
21
CORPORATE PRESENTATION 08/07/2019MAYOLY
SPINDLER
AT A GLANCE
22€182 million 41%
of turnover generated
turnover outside of France.
Pharmaceuticals: 72%
Diagnostic : 7%
Dermo-cosmetics: 13%
Production: 7%
Over 900 3 production sites
employees worldwide, near Paris: 1 in Chatou
including 600 in France. and 2 in Dammarie-les-lys
23
Figures as at 12/31/2018.Committed to your
health.
Every day.You can also read
